Heart attack risk in people with HIV may be falling – but not in women
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation
Protected T-cells persist and proliferate in HIV gene therapy study
Raltegravir has the edge over two protease inhibitors in three-drug comparison study
The 'Boston patients' experience HIV rebound after stem cell transplants
Male life expectancy nine years shorter due to lower male uptake of HIV treatment in rural South Africa
Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART
HIV attachment inhibitor BMS-663068 shows good safety and efficacy in phase 2b study
Monkey studies confirm viability of injectable PrEP drug
